Ipsen (IPN) H1 2024 earnings summary

Executive summary

• Total sales grew by 9.5% in H1 2024 to €1,659m, with a core operating margin of 32.4% and free cash flow of €394m.

• IFRS consolidated net profit increased 19.1% to €232m, supported by lower financial and tax expenses.

• Achieved key U.S. launches and approvals for Onivyde (first-line pancreatic cancer) and Iqirvo (second-line PBC), with CHMP opinions pending.

• Pipeline advanced with ex-U.S. licensing of tovorafenib for pediatric oncology and multiple early-stage deals in oncology and neuroscience.

• Upgraded FY 2024 guidance for total sales growth and core operating margin.

Financial highlights

• Total sales reached €1,659m, up 9.5% at constant exchange rates; core operating income rose 2.8% to €538m.

• Free cash flow increased 5.9% to €394m; closing net debt reduced to €6.8m from €272m in H1 2023.

• IFRS consolidated net profit increased 19.1% to €232m; EBITDA up 2.6% to €583m.

• Unfavorable FX impact of -1.5% on H1 2024 sales.

Outlook and guidance

• Upgraded 2024 guidance: total sales growth expected above 7% at constant exchange rates, with core operating margin above 30%.

• Lower profitability expected in H2 due to increased investment, seasonality, and currency headwinds (~1% impact).

• Guidance assumes accelerated Somatuline erosion from increased generic competition, especially in the US.